Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer
American Journal of Clinical Pathology · 05.07.2024 · 162 (1) · 17-27
DOI: 10.1093/ajcp/aqae002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 20.02.2024. Verfasst von Belinda L Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Arizona College of Medicine, Tucson, AZ, US. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Colitis, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Department of Pathology Internal Funding, University of Arizona College of Medicine, Tucson, Arizona.
Abstract (Originalsprache)
Objectives
Immune checkpoint inhibitors, a revolutionary class of cancer immunotherapy drugs, have transformed cancer treatment by bolstering antitumor immunity for various advanced-stage solid cancers. The US Food and Drug Administration has approved 7 immune checkpoint inhibitors that target 3 major immune checkpoint proteins: cytotoxic T-lymphocyte–associated protein 4, programmed cell death 1 protein, and programmed cell death 1 ligand 1. In addition to their remarkable efficacy, however, these inhibitors have been observed causing immune-related adverse events, particularly immune checkpoint inhibitor–related colitis, which often results in severe or life-threatening clinical issues.
Methods
The diagnosis of immune checkpoint inhibitor–related colitis relies on incorporation of clinical evaluation as well as endoscopic and histopathologic examination, with exclusion of other potential etiologies.
Results
The common histopathologic manifestations of immune checkpoint inhibitor–related colitis are acute active colitis, chronic active colitis, microscopic colitis (collagenous or lymphocytic), and ischemic colitis, with patterns overlapping. Notably, enterocyte apoptosis is a unique feature of immune checkpoint inhibitor toxicity. The proposed mechanisms for the pathogenesis of immune checkpoint inhibitor–related colitis are primarily associated with autoimmune-type dysregulation and gut microbiome alteration. This review summarizes the clinical and pathologic characteristics of immune checkpoint inhibitor–related colitis and elucidates its underlying pathogenic mechanisms.
Conclusions
Future successful management of this form of colitis relies on our comprehension of the intricate interplay between tumoral and systemic immune responses to immune checkpoint inhibitors and innovative approaches to modify these responses, along with specific immune cell populations, to preclude immune-related adverse events while achieving antitumor therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Arizona College of Medicine, Tucson, AZ, US.
- Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, US.
ORCID-Profile: Belinda L Sun
Förderung
- Department of Pathology Internal Funding, University of Arizona College of Medicine, Tucson, Arizona
Zitieren
APA
Sun, B. L., Elliott, A. S., Nolte, D., & Sun, X. (2024). Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer. American Journal of Clinical Pathology, 162(1), 17-27. https://doi.org/10.1093/ajcp/aqae002
Vancouver
Sun BL, Elliott AS, Nolte D, Sun X. Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer. American Journal of Clinical Pathology. 2024;162(1):17-27. doi:10.1093/ajcp/aqae002
BibTeX
@article{Sun2024,
author = {Sun, Belinda L and Elliott, Alexis S and Nolte, David and Sun, Xiaoguang},
title = {Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer},
journal = {American Journal of Clinical Pathology},
year = {2024},
volume = {162},
number = {1},
pages = {17--27},
doi = {10.1093/ajcp/aqae002}
}
EUVIMED